# Tourmaline Bio, Inc.

Tourmaline Bio, Inc. is a company headquartered in New York, NY, United States.

## Company overview

- **Legal name:** Tourmaline Bio, Inc.
- **Former names in filing history:** Talaris Therapeutics, Inc. (2020-10-07 to 2023-10-18)
- **Classification:** Company
- **Industry (SIC):** 2836 — Biological Products, (No Diagnostic Substances)
- **Headquarters:** New York, NY, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001827506

## About

Tourmaline Bio, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001827506, and its reported industry is Biological Products, (No Diagnostic Substances). In 10-K filed on 2025-03-13, it reported net income of USD -73,210,000; total assets of USD 309,001,000 for the fiscal period ended 2024-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2024 (period ended 2024-12-31)

- **Net income:** -$73.2M (USD -73,210,000)
- **Total assets:** $309.0M (USD 309,001,000)
- **Cash and equivalents:** $30.5M (USD 30,506,000)
- **Operating cash flow:** -$77.3M (USD -77,263,000)

### FY2023 (period ended 2023-12-31)

- **Net income:** -$42.1M (USD -42,124,000)
- **Total assets:** $210.3M (USD 210,295,000)
- **Cash and equivalents:** $140.7M (USD 140,726,000)
- **Operating cash flow:** -$28.1M (USD -28,081,000)

### FY2022 (period ended 2022-12-31)

- **Net income:** -$73.9M (USD -73,894,000)
- **Total assets:** $193.7M (USD 193,715,000)
- **Cash and equivalents:** $13.7M (USD 13,670,000)
- **Operating cash flow:** -$60.9M (USD -60,857,000)
- **Later filings:** Net income, Total assets, Cash and equivalents, Operating cash flow: shown as originally filed; later filings report different values for the same periods.

### FY2021 (period ended 2021-12-31)

- **Net income:** -$47.8M (USD -47,833,000)
- **Total assets:** $251.4M (USD 251,422,000)
- **Cash and equivalents:** $18.6M (USD 18,614,000)
- **Operating cash flow:** -$40.0M (USD -39,988,000)
- **Later filings:** Net income, Operating cash flow: shown as originally filed; later filings report different values for the same periods.

## Recent SEC filings

- Form 8-K — filed 2025-10-28 — period 2025-10-28 — FORM 8-K
- Form 8-K — filed 2025-09-12 — period 2025-09-08 — 8-K
- Form 8-K — filed 2025-09-09 — period 2025-09-08 — 8-K
- Form 10-Q — filed 2025-08-13 — period 2025-06-30 — 10-Q
- Form 8-K — filed 2025-08-13 — period 2025-08-13 — 8-K
- Form 8-K — filed 2025-06-09 — period 2025-06-09 — 8-K
- Form 8-K — filed 2025-06-06 — period 2025-06-04 — 8-K
- Form 8-K — filed 2025-05-20 — period 2025-05-20 — 8-K
- Form 10-Q — filed 2025-05-02 — period 2025-03-31 — 10-Q
- Form 8-K — filed 2025-05-02 — period 2025-05-02 — 8-K
- Form DEF 14A — filed 2025-04-21 — period 2025-06-04 — DEF 14A
- Form 10-K — filed 2025-03-13 — period 2024-12-31 — 10-K

---

Updated: 2026-10-23T20:09:28Z

Canonical page: https://altss.com/profile/tourmaline-bio-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology